A randomized, multicenter, open-label, phase III study of DB-1303 versus investigator-choice chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-low, hormone receptor-positive (HR+) metastatic breast cancer whose disease has progressed on endocrine therapy.
Reason for the study: You have breast cancer with one or more hormone receptor-positive (HR+) breast tumors and are being treated with standard therapy. The sponsor named above is currently developing a new therapy. Therefore, the investigational drug called DB-1303 will be tested in the study. The sponsor wants to determine whether the investigational drug is effective compared to standard therapy and whether it is safe for patients with your type of breast cancer.
The investigational drug being tested: DB-1303 is still in clinical trials and has not yet been approved for your treatment. As of December 14, 2023, approximately 235 people have received DB-1303.
